A thorough understanding of the role of lncRNA in prostate cancer pathogenesis; Current knowledge and future research directions

Pathol Res Pract. 2023 Aug:248:154666. doi: 10.1016/j.prp.2023.154666. Epub 2023 Jul 3.

Abstract

In the entire world, prostate cancer (PCa) is one of the most common and deadly cancers. Treatment failure is still common among patients, despite PCa diagnosis and treatment improvements. Inadequate early diagnostic markers and the emergence of resistance to conventional therapeutic approaches, particularly androgen-deprivation therapy, are the causes of this. Long non-coding RNAs (lncRNAs), as an essential group of regulatory molecules, have been reported to be dysregulated through prostate tumorigenesis and hold great promise as diagnostic targets. Besides, lncRNAs regulate the malignant features of PCa cells, such as proliferation, invasion, metastasis, and drug resistance. These multifunctional RNA molecules interact with other molecular effectors like miRNAs and transcription factors to modulate various signaling pathways, including AR signaling. This study aimed to compile new knowledge regarding the role of lncRNA through prostate tumorigenesis in terms of their effects on the various malignant characteristics of PCa cells; in light of these characteristics and the significant potential of lncRNAs as diagnostic and therapeutic targets for PCa. AVAILABILITY OF DATA AND MATERIALS: Not applicable.

Keywords: Drug resistance; LncRNAs; Metastasis; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists
  • Carcinogenesis / genetics
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Male
  • MicroRNAs*
  • Prostatic Neoplasms* / pathology
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding
  • Androgen Antagonists
  • MicroRNAs